MacroGenics is a clinical-stage biopharmaceutical company developing next-generation antibody-based therapies to improve the lives of cancer patients.

MacroGenics is advancing a broad pipeline of novel product candidates spanning oncology, hematology, and autoimmune applications. The Company has a proven track record of developing FDA-approved therapies in collaboration with global biopharmaceutical partners.

MacroGenics leverages multiple platform technologies capable of delivering additional product candidates, including: antibody-drug conjugates (ADCs), bispecific checkpoint antibodies, and next-generation T-cell engagers.